India Pharma Is Entering Its Innovation Era — Are Investors Paying Attention?

For decades, India has been known as the “pharmacy of the world.” But the next chapter of Indian healthcare may not be written by low-cost generic medicines alone. A new wave is emerging, one built on innovation, complex therapies, specialty drugs, and global patient needs. The question now is not whether Indian pharma can manufacture at scale, but whether it can move up the value chain.

India Biopharma Sector Growth

India’s biopharma sector has historically played a vital role in global healthcare access. A large share of prescriptions worldwide is filled by medicines of Indian origin, showing the country’s manufacturing strength and global relevance. However, in value terms, India’s share of the global biopharma market remains relatively small. This gap creates both a challenge and an opportunity.

Source: IPA Report, 2023 GoI Annual Report on Pharmaceuticals. Ministry of Chemicals and Fertilizers, Bernstein Estimates and Analysis

As the Covid-19-led rally fades and pricing pressure continues to weigh on US generics margins, Indian biopharma companies are shifting focus toward productivity, quality systems, talent reskilling, and operating leverage across domestic and emerging markets. Key investor questions now center on whether the sector can move beyond vanilla generics and structurally invest in innovation-led growth, while capturing opportunities in Europe, emerging markets, GLP-1-driven domestic demand, and enterprise AI adoption.

India already plays a critical role in global healthcare, with roughly one in six prescriptions worldwide supplied by drugs of Indian origin. However, despite accounting for nearly 65% of global prescription volumes, India represents only about $57 billion, or 3%, of global biopharma value which is expected that this value gap is set to narrow materially.

The Indian biopharma sector is projected to expand from $57Bn in 2025 to $99Bn by 2030E and $152Bn by 2035E, implying an estimated 10% CAGR over the next decade. This growth reflects a steady transition from volume-led participation in bulk drugs and vanilla generics toward higher-value opportunities across differentiated products, domestic formulations, emerging markets, and innovation-led platforms. The next phase of sector expansion is therefore expected to be driven not only by scale, but also by improved value capture.

Global Biopharma Shifts Toward Specialty, Biologics, and DNA/RNA Medicines

The evolution of global disease burden and the therapy modalities required to address it remains a key area of debate for industry participants and investors. Over the past century, the global disease profile has shifted meaningfully toward three broad categories: lifestyle-led conditions such as obesity, dermatological disorders, and infertility; ageing-linked diseases such as Alzheimer’s and Parkinson’s; and pollution-related chronic illnesses, including certain cancers, respiratory diseases, and immunological disorders.

This shift is affecting a much larger patient base than in prior decades. A bottom-up proprietary disease model indicates that each of these three disease buckets could add an average of around 100 million patients annually (As per Bernstein Report on India Healthcare: Innovation Power Decade). The scale and complexity of this burden require a shift in treatment approach, moving beyond conventional chemistry-led therapies toward specialty, biologics, and targeted medicines.

As a result, innovation across the Indian biopharma value chain is expected to become increasingly important. By 2040, specialty therapies, biologics, and DNA/RNA-based modalities are likely to account for the overwhelming majority of global drug development, shaping the future direction of Indian biopharma.

As per the Bernstein Report, the Indian biopharma market is expected to grow at a 10–11% CAGR over the next three to five years, with chronic therapies expanding at nearly 1.3–1.4x the overall market growth rate. This should support a gradual mix shift toward higher-value, recurring therapy segments. Market leadership is also likely to become more concentrated. Therapy-area leaders are expected to outpace the broader market, gaining share from smaller players with weaker brand depth, field productivity, and execution capabilities. By 2030, the top 10 biopharma companies could account for nearly half of the domestic market. Key listed beneficiaries of this trend include Sun Pharma, Zydus, and Lupin, given their strong chronic therapy presence, scale advantages, and established domestic franchises.

Source: Evaluate Pharma, BCG report 2025, Bernstein Estimates and Analysis

From Generics to Rainmakers: Indian Biopharma’s Innovation Pyramid

For Indian biopharma, the next phase of growth is likely to be defined by a shift from manufacturing-led scale to innovation-led value creation. This does not necessarily require a full pivot toward high-risk blockbuster drug discovery. A more practical route lies in incremental innovation, where companies enhance existing medicines through new indications, improved formulations, novel delivery systems, drug-device combinations, or targeted therapies for niche patient groups.

This innovation pathway is well aligned with India’s established strengths in formulation development, manufacturing scale, regulatory filings, and cost-efficient execution. As the sector moves up the innovation pyramid, the opportunity expands from basic generics toward complex specialty products and a high-value “Rainmakers” niche, differentiated products with fewer competitors, stronger pricing power, and better margin potential.

Traditional generics will continue to generate cash flows, but the next growth engine is expected to come from products with deeper differentiation and higher entry barriers. Execution, however, will be uneven across companies. Success will require patient capital, strong quality systems, regulatory discipline, scientific talent, and focused pipelines. Companies with stronger balance sheets and clearer innovation strategies are likely to be better positioned than those constrained by leverage or execution gaps.

Source: Company reports; US FDA approval guidance documents for industry; Bernstein analysis

Conclusion: From Manufacturing Scale to Innovation Strength

Indian pharma appears to be entering a defining transition phase. Its legacy as a high-volume, cost-efficient generic supplier remains highly relevant, but the next phase of value creation is likely to depend on how effectively companies move up the innovation curve.

For readers, investors, and industry participants, the central question is no longer whether India can manufacture at scale. That capability is well established. The real question is which Indian biopharma companies can translate this manufacturing advantage into differentiated products, stronger pricing power, and a more meaningful role in global innovation.